ReviewGastrointestinal dysfunction in Parkinson’s disease☆,☆☆,☆☆☆
Introduction
While recognition that Parkinson’s disease (PD) involves far more than just motor dysfunction has blossomed in recent years, James Parkinson quite clearly describes some of the nonmotor aspects of the disorder in his 1817 treatise [1]. In particular, he indicates his awareness of gastrointestinal (GI) dysfunction with vivid descriptions of drooling, dysphagia, and bowel dysfunction in some of the individuals he examined.
A much more detailed picture of the presence and extent of GI dysfunction in PD is now emerging and abnormalities or disturbances in function at virtually all levels of the GI system have been identified. Weight loss, dental deterioration, salivary excess, dysphagia, impaired gastric emptying, decreased bowel movement frequency, and difficulty with the act of defecation itself all may occur in the setting of PD.
In addition to being the source of significant clinical symptoms and dysfunction in individuals with PD, a much more fundamental role of the GI system in the genesis of PD has also been hypothesized. It has now been suggested that the enteric nervous system (ENS) may actually be the port of entry of the pathologic process that eventually culminates in the clinical picture of PD.
Section snippets
Weight loss
Unintended weight loss is frequently reported by patients with PD. In one study, weight loss was documented in 52% of persons with PD [2]. The weight loss was rather modest in most individuals, but exceeded 28 pounds in 22% of the study participants [2]. In another study, the mean weight loss of PD patients was 7.2 pounds, compared with a weight gain of 2.1 pounds in the control group [3]. Women with PD are more likely to lose weight than men [4].
The reason for weight loss in PD is not at all
Dental deterioration
An increased incidence of oral health problems, such as loss of teeth, chewing difficulty, and denture discomfort has been described in the setting of PD [8]. Increased periodontal pathology has also been reported [9]. However, disproportionate deterioration in dental function has not been identified in all studies of PD patients [10], [11]. Even though no specific treatment recommendations regarding dental difficulties in PD patients have been formulated, increased attention to and regular
Salivary excess
The presence of excess saliva within the mouth is evident in many persons with PD [16], [17], [18]. Survey studies indicate that 70–78% of PD patients are aware of excessive amounts of saliva, compared with only 6% of controls [19], [20].
The excess saliva noted by PD patients is not the result of increased salivary production. In fact, saliva production is actually decreased in the setting of PD [21], [22], [23], [24]. Saliva accumulation is, instead, the consequence of diminished frequency and
Dysphagia
Survey studies vary broadly in their recording of the presence of difficulty swallowing in individuals with PD, with reports ranging from 30% to over 80% [19], [20], [30], [31]. Studies utilizing objective measures, such as the modified barium swallow (MBS) test, provide more consistent – and even higher – percentages of functional impairment, with abnormalities noted in 75–97% of individuals [32], [33], [34]. It is not entirely clear whether dysphagia is a reflection of disease progression.
Nausea/gastroparesis
Nausea in the setting of PD is most often due to dopaminergic antiparkinson medication. However, nausea may also develop in individuals who are receiving no antiparkinson medication. In one study, nausea was present in 16% of untreated PD patients and a sense of bloating in 43% [20]. Other investigators have subsequently documented the presence of impaired or delayed gastric emptying in PD as the probable etiology for these symptoms [52], [53], [54], [55], [56]. Most studies indicate that
Decreased bowel movement frequency
Diminished frequency of bowel movements is probably the most widely recognized aspect of GI dysfunction in PD. The actual frequency with which this problem occurs, however, is not entirely clear. Even when the currently accepted dividing line of fewer than three bowel movements per week is employed as a measure, the reported number of PD patients experiencing decreased bowel movement frequency ranges from 20–89% in various studies [20], [79], [80], [81]. Survey studies have indicated that the
Defecatory difficulty
Difficulty with the act of defecation, resulting in excessive straining, pain, and incomplete evacuation, may be present in up to two-thirds of individuals with PD [20], [97]. For effective elimination to occur, coordinated action of multiple muscles must take place. The internal and external anal sphincter muscles and puborectalis muscle must relax while adequate rectosigmoid tone must develop and the abdominal wall muscles, diaphragm and even glottic muscles must contract in order to increase
Pathophysiology of GI dysfunction in PD
While dopaminergic deficiency secondary to nigrostriatal damage may be responsible for some aspects of GI dysfunction in PD, it is also quite clear that additional sites of involvement, both within the central nervous system (CNS) and beyond it, also play important roles. The dorsal motor nucleus of the vagus (DMV), which provides parasympathetic innervation to much of the GI tract, is profoundly involved in PD [112], [113]. In fact, recent work by Braak and colleagues has demonstrated that the
Conclusion
GI dysfunction is receiving increasing attention and recognition as an important clinical component of PD. Beyond this, however, evidence is now emerging that the ENS may even be the pathophysiologic “ground zero” of the disorder. GI dysfunction in PD involves virtually all levels of the GI tract and is the source of significant functional impairment for many individuals with PD. All of this makes it important for neurologists and other clinicians to be familiar with the GI features of PD and
References (120)
- et al.
Weight change and body composition in patients with Parkinson’s disease
J Am Diet Assoc
(1995) Gastrointestinal dysfunction in Parkinson’s disease
Lancet Neurol
(2003)- et al.
Weight and body mass index in Parkinson’s disease patients after deep brain stimulation surgery
Parkinsonism Relat Disord
(2005) - et al.
Is drooling secondary to a swallowing disorder in patients with Parkinson’s disease?
Parkinsonism Relat Disord
(2008) - et al.
Botulinum toxin: clinical use
Parkinsonism Relat Disord
(2006) - et al.
Swallowing difficulty in Parkinson’s disease
Clin Neurol Neurosurg
(1997) - et al.
Swallowing disorders in Parkinson’s disease
Parkinsonism Relat Disord
(2003) - et al.
Mechanisms of oral-pharyngeal dysphagia in patients with Parkinson’s disease
Gastroenterology
(1996) - et al.
Impaired gastric emptying of a solid test meal in patients with Parkinson’s disease using 13C-sodium octanoate breath test
Neurosci Lett
(2005) - et al.
Increased gastric motility during 5-HT4 agonist therapy reduces response fluctuations in Parkinson’s disease
Parkinsonism Relat Disord
(2005)
Oral erythromycin and symptomatic relief of gastroparesis: a systematic review
Am J Gastroenterol
Mirtazapine for severe gastroparesis unresponsive to conventional prokinetic treatment
Psychosomatics
Gastric electrical stimulation for gastroparesis
J Am Coll Surg
Autonomic dysfunction in Parkinson’s disease: a comprehensive symptom survey
Parkinsonism Relat Disord
Questionnaire-based assessment of pelvic organ dysfunction in Parkinson’s disease
Auton Neurosci
An essay on the shaking palsy
Diet, body size and micronutrient status in Parkinson’s disease
Eur J Clin Nutr
Parkinson’s disease and weight loss: a study with anthropometric and nutritional assessment
Clin Auton Res
Compulsive eating and weight gain related to dopamine agonist use
Mov Disord
Oral health conditions in patients with Parkinson’s disease
J Epidemiol
Increased periodontal pathology in Parkinson’s disease
J Neurol
Influence of Parkinson’s disease on oral health
Acta Odontol Scand
Oral health of patients with Parkinson’s disease: factors related to their better dental status
Tohoku J Exp Med
Bruxism as a presenting feature of Parkinson’s disease
J Assoc Physicians India
An appliance for management of TMJ pain as a complication of Parkinson’s disease
Cranio
Habitual mandibular dislocation in two patients with Parkinson’s disease
Rinsho Shinkeigaku
Burning mouth in Parkinson’s disease sufferers
Gerodontology
Sialorrhoea and drooling in patients with Parkinson’s disease: epidemiology and management
Drugs Aging
Impact of drooling in Parkinson’s disease
J Neurol
Sialorrhea in Parkinson’s disease: a review
Mov Disord
Alimentary disorder in parkinsonism
Aust Ann Med
Gastrointestinal symptoms in Parkinson’s disease
Mov Disord
Salivary symptoms in Parkinson disease
Arch Neurol
A study of salivary secretion in Parkinson’s disease
Clin Neuropharmacol
Salivary production in Parkinson’s disease
Mov Disord
Quantitative study of salivary secretion in Parkinson’s disease
Mov Disord
Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study
Mov Disord
Ipratropium bromide spray as treatment for sialorrhea in Parkinson’s disease
Mov Disord
Long-term follow-up of tympanic neurectomy for sialorrhea
Laryngoscope
Referral criteria for speech and language therapy assessment of dysphagia caused by idiopathic Parkinson’s disease
Acta Neurol Scand
Prepharyngeal dysphagia in Parkinson’s disease
Dysphagia
Swallowing abnormalities and their response to treatment in Parkinson’s disease
Neurology
Pharyngo-esophageal dysphagia in Parkinson’s disease
Dysphagia
Asymptomatic swallowing disorders in elderly patients with Parkinson’s disease: a description of findings on clinical examination and videofluoroscopy in sixteen patients
Age Aging
Dysphagia, a reversible cause not to be forgotten
Postgrad Med J
Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders
Arch Neurol
Videofluorographic study of swallowing in Parkinson’s disease
Dysphagia
Swallowing and speech production in Parkinson’s disease
Ann Neurol
Radiological assessment of dysphagia in Parkinson’s disease
Br J Radiol
Cricopharyngeal dysfunction in Parkinson’s disease: role in dysphagia and response to myotomy
Mov Disord
Cited by (226)
Probiotics for constipation and gut microbiota in Parkinson's disease
2022, Parkinsonism and Related DisordersLong-Term Risks of Parkinson's Disease, Surgery, and Colorectal Cancer in Patients With Slow-Transit Constipation
2021, Clinical Gastroenterology and HepatologyGastrointestinal disorders in hyperkinetic movement disorders and ataxia
2021, Parkinsonism and Related DisordersNeuroimmune Connectomes in the Gut and Their Implications in Parkinson’s Disease
2024, Molecular Neurobiology
- ☆
Disclosures (2009–2010): Honoraria for lectures: Boehringer-Ingelheim, Novartis, Teva. Honoraria for consulting: Solvay, Theravance, Genactis, Schlesinger Associates. Research Grants/Contracts: Novartis, Boehringer-Ingelheim, UCB/Schwarz, Santhera, Molecular Biometrics. Royalties (for books edited): CRC Press (Taylor & Francis), Humana Press. Legal Consulting: Spriggs & Hollingsworth, Davis Graham & Stubbs, Tucker Ellis & West.
- ☆☆
This paper was presented at the XVIII WFN World Congress on Parkinson's Disease and Related Disorders Miami December 2009.
- ☆☆☆
The review of this paper was entirely handled by the Co-Editor-in-Chief Prof. Z.K. Wszolek.